Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects (NSERC partnered)

University of Toronto

$232,628.00

Microfluidic drug screening in complex vascular microenvironments

EF 2009-10

Résumé
Diseases of the heart and blood vessels are responsible for one third of all deaths in Canada and cost our economy more than any other illness. Currently, treatments for the most common cardiovascular diseases are ineffective, invasive, or non-existent. With the population in Canada expanding and aging, the need for new interventions to prevent or cure cardiovascular diseases has never been greater. A core technology used to discover new drugs involves growing cardiovascular cells in plastic containers, treating them with candidate drugs, and studying them to determine how they respond to the drug and the molecular mechanisms that cause the response. These systems fail to mimic many key aspects of the real environment experienced by cardiovascular cells, including the three-dimensional matrix they live in, the other cells they interact with, and the forces that flowing blood exerts on them. Cells respond to cues from their environment, and therefore cells grown on plastic do not behave as they do in the body. These limitations significantly hinder the ability of current technologies to generate relevant and novel biological discoveries. The overall goal of the current project is to address the limitations of current cell culture technologies by developing novel ''microchips'' for basic science research and drug discovery that mimic the complex environment in a blood vessel. The systems will be based on microfluidics technology, which allows for precise control of the cell environment. Key features to be mimicked include the structure and composition of the tissue, multiple interacting cell types, and complex blood flow patterns. We will use this novel technology to study the molecular mechanisms that regulate hardening of blood vessels (atherosclerosis) and to screen over 5,000 compounds as potential drugs for the treatment of atherosclerosis. Our interdisciplinary team is ideally-equipped to achieve our goals, with significant impact expected. In the short-term, we will develop enabling technologies for cardiovascular drug discovery and will identify potential therapeutics for atherosclerosis. Long-term, this technology and the fundamental knowledge gained through its application will result in improved therapies for cardiovascular diseases. We will also equip highly qualified personnel with the interdisciplinary tools required to turn ideas into innovations that will solve Canada's most important health challenges and improve our economic competitiveness
Programme
Collaborative Health Research Projects (NSERC partnered)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
198911
Name
Simmons Craig A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Unable to allocate
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Microfluidic drug screening in complex vascular microenvironments
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$232,628
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Microfluidics
Abstract
Diseases of the heart and blood vessels are responsible for one third of all deaths in Canada and cost our economy more than any other illness. Currently, treatments for the most common cardiovascular diseases are ineffective, invasive, or non-existent. With the population in Canada expanding and aging, the need for new interventions to prevent or cure cardiovascular diseases has never been greater. A core technology used to discover new drugs involves growing cardiovascular cells in plastic containers, treating them with candidate drugs, and studying them to determine how they respond to the drug and the molecular mechanisms that cause the response. These systems fail to mimic many key aspects of the real environment experienced by cardiovascular cells, including the three-dimensional matrix they live in, the other cells they interact with, and the forces that flowing blood exerts on them. Cells respond to cues from their environment, and therefore cells grown on plastic do not behave as they do in the body. These limitations significantly hinder the ability of current technologies to generate relevant and novel biological discoveries. The overall goal of the current project is to address the limitations of current cell culture technologies by developing novel ''microchips'' for basic science research and drug discovery that mimic the complex environment in a blood vessel. The systems will be based on microfluidics technology, which allows for precise control of the cell environment. Key features to be mimicked include the structure and composition of the tissue, multiple interacting cell types, and complex blood flow patterns. We will use this novel technology to study the molecular mechanisms that regulate hardening of blood vessels (atherosclerosis) and to screen over 5,000 compounds as potential drugs for the treatment of atherosclerosis. Our interdisciplinary team is ideally-equipped to achieve our goals, with significant impact expected. In the short-term, we will develop enabling technologies for cardiovascular drug discovery and will identify potential therapeutics for atherosclerosis. Long-term, this technology and the fundamental knowledge gained through its application will result in improved therapies for cardiovascular diseases. We will also equip highly qualified personnel with the interdisciplinary tools required to turn ideas into innovations that will solve Canada's most important health challenges and improve our economic competitiveness
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Simmons, Craig A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $232,628~ $0~